Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

BackgroundFruquintinib and regorafenib have been approved for the third-line therapy of metastatic colorectal cancer (mCRC) in China. However, at present, there is a lack of head-to-head clinical trials on the comparison of efficacy and safety between the two drugs.Materials and methodsThe data of p...

Full description

Bibliographic Details
Main Authors: Ya-Ya Deng, Xin-Yue Zhang, Peng-Fei Zhu, Hong-Rui Lu, Qian Liu, Shuang-Yue Pan, Zhe-Ling Chen, Liu Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
fruquintinib
regorafenib
immunotherapy
advanced colorectal cancer
real-world study
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1097911/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1097911/full

Similar Items